Replacement oral ethinyloestradiol therapy for gonadal dysgenesis: growth and adrenal androgen studies

A. W. Lucky, S. P. Marynick, R. W. Rebar, G. B. Cutler, M. Glen, R. E. Johnsonbaugh, D. L. Loriaux

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

We have studied growth and adrenal dehydroepiandrosterone (DHA) responses to iv synthetic andrenocorticotrophic hormone (ACTH, Cortrosyn) in 6 girls with gonadal dysgenesis before and during treatment with low-dose ethinyloestradiol (EOe2). In all patients there was a statisfactory induction of secondary sexual characteristics including increase in breasts and pubic hair and onset of withdrawal bleeding within 6 months of therapy. Height velocity increased from 2.8 ± 0.9 cm/year pre-treatment to 5.3 ± 1.5 cm/year (P<0.02) in the first year. There was deceleration to 1.9 ± 1.1 cm/year in the second year. There was no disproportionate advancement in bone age and thus, presumably, no loss of ultimate height. We could demonstrate no change in basal or ACTH-stimulated levels of DHA, a specific adrenal androgen, to account for the increased pubic hair and growth in these patients.

Original languageEnglish (US)
Pages (from-to)519-528
Number of pages10
JournalUnknown Journal
Volume91
Issue number3
DOIs
StatePublished - 1979

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Replacement oral ethinyloestradiol therapy for gonadal dysgenesis: growth and adrenal androgen studies'. Together they form a unique fingerprint.

  • Cite this

    Lucky, A. W., Marynick, S. P., Rebar, R. W., Cutler, G. B., Glen, M., Johnsonbaugh, R. E., & Loriaux, D. L. (1979). Replacement oral ethinyloestradiol therapy for gonadal dysgenesis: growth and adrenal androgen studies. Unknown Journal, 91(3), 519-528. https://doi.org/10.1530/acta.0.0910519